Display options
Cite
Mori Y, Ko E, Furrer R, et al. Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats. Endocr Connect. 2018;7(5):739-748doi: 10.1530/EC-17-0358.
Mori, Y., Ko, E., Furrer, R., Qu, L. C., Wiber, S. C., Fantus, I. G., Thevis, M., Medline, A., & Giacca, A. (2018). Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats. Endocrine connections, 7(5), 739-748. https://doi.org/10.1530/EC-17-0358
Mori, Yusaku, et al. "Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats." Endocrine connections vol. 7,5 (2018): 739-748. doi: https://doi.org/10.1530/EC-17-0358
Mori Y, Ko E, Furrer R, Qu LC, Wiber SC, Fantus IG, Thevis M, Medline A, Giacca A. Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats. Endocr Connect. 2018 May;7(5):739-748. doi: 10.1530/EC-17-0358. Epub 2018 Apr 24. PMID: 29692348; PMCID: PMC5958747.
Copy Download .nbib Format: NLM
Share it on

Endocr Connect. 2018 May;7(5):739-748. doi: 10.1530/EC-17-0358. Epub 2018 Apr 24.

Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats.

Endocrine connections

Yusaku Mori, Eunhyoung Ko, Rudolf Furrer, Linda C Qu, Stuart C Wiber, I George Fantus, Mario Thevis, Alan Medline, Adria Giacca

Affiliations

  1. Department of PhysiologyFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  2. Department of DiabetesMetabolism, and Endocrinology, Showa University School of Medicine, Shinagawa, Tokyo, Japan.
  3. Department of Nutritional SciencesFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  4. Departments of Medicine and PhysiologyFaculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  5. Toronto General Research InstituteUniversity Health Network, Toronto, Ontario, Canada.
  6. Division of Endocrinology and MetabolismLeadership Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
  7. Center for Preventive Doping Research and Institute of BiochemistryGerman Sport University Cologne, Cologne, Germany.
  8. Department of Laboratory Medicine & PathobiologyUniversity of Toronto, Toronto, Ontario, Canada.
  9. Department of PathologyHumber River Regional Hospital, Toronto, Ontario, Canada.
  10. Departments of Physiology and MedicineInstitute of Medical Science, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada [email protected].

PMID: 29692348 PMCID: PMC5958747 DOI: 10.1530/EC-17-0358

Abstract

It is not fully clarified whether insulin glargine, an analogue with a high affinity for insulin-like growth factor-1 receptor (IGF-1R), increases the risk for cancers that abundantly express IGF-1R such as breast cancer or some types of breast cancer. To gain insight into this issue, female Sprague-Dawley rats fed a high-fat diet were given the carcinogen N-methyl-N-nitrosourea and randomly assigned to vehicle (control), NPH (unmodified human insulin), glargine or detemir (

© 2018 The authors.

Keywords: detemir; glargine; insulin; mammary tumour; rat

References

  1. Diabetes Care. 2010 Sep;33(9):1997-2003 - PubMed
  2. Int J Toxicol. 2012 Mar;31(2):137-42 - PubMed
  3. J Natl Cancer Inst. 1981 Jul;67(1):51-6 - PubMed
  4. Cancer Res. 1972 Feb;32(2):233-8 - PubMed
  5. Diabetes Care. 2013 Nov;36(11):3517-25 - PubMed
  6. Drug Test Anal. 2014 Nov-Dec;6(11-12):1125-32 - PubMed
  7. Carcinogenesis. 2001 Dec;22(12):2039-47 - PubMed
  8. Diabetes. 2013 Jul;62(7):2539-44 - PubMed
  9. Oncogene. 2002 Feb 14;21(8):1299-303 - PubMed
  10. Diabetes Care. 2006 Feb;29(2):254-8 - PubMed
  11. Acta Oncol. 2011 Jun;50(5):685-93 - PubMed
  12. Diabetes. 2010 May;59(5):1254-60 - PubMed
  13. Diabetes Metab Res Rev. 2009 Jan;25(1):41-9 - PubMed
  14. Diabetologia. 2009 Sep;52(9):1732-44 - PubMed
  15. Diabetologia. 2011 Sep;54(9):2226-31 - PubMed
  16. Diabetes Care. 2003 Jun;26(6):1752-8 - PubMed
  17. Diabetologia. 2012 Jan;55(1):51-62 - PubMed
  18. Diabetes Care. 2014;37(1):134-43 - PubMed
  19. Diabetologia. 2009 Sep;52(9):1766-77 - PubMed
  20. Diabetologia. 2009 Sep;52(9):1755-65 - PubMed
  21. Int J Biol Markers. 2012 Oct 08;27(3):e241-6 - PubMed
  22. Metabolism. 2000 Nov;49(11):1411-6 - PubMed
  23. J Diabetes Res. 2016;2016:8310516 - PubMed
  24. N Engl J Med. 2012 Jul 26;367(4):319-28 - PubMed
  25. Carcinogenesis. 1998 Apr;19(4):699-702 - PubMed
  26. Cancer Causes Control. 2011 Aug;22(8):1163-71 - PubMed
  27. Expert Opin Investig Drugs. 1999 Sep;8(9):1431-42 - PubMed
  28. Diabetes Care. 2014;37(5):1360-6 - PubMed
  29. Breast Cancer Res. 2017 Feb 7;19(1):14 - PubMed
  30. Diabetologia. 1997 Jul;40 Suppl 2:S25-31 - PubMed
  31. Diabetologia. 2011 Sep;54(9):2254-62 - PubMed
  32. PLoS One. 2010 Mar 04;5(3):e9540 - PubMed
  33. Diabetologia. 2016 Sep;59(9):2018-25 - PubMed
  34. Cancer Res. 2010 Jan 15;70(2):741-51 - PubMed
  35. Clin Cancer Res. 1999 Jul;5(7):1935-44 - PubMed
  36. J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):187-200 - PubMed
  37. Breast Cancer Res. 2015 Feb 18;17:14 - PubMed
  38. Cancer Lett. 1996 Feb 27;100(1-2):169-79 - PubMed
  39. J Clin Oncol. 2017 Nov 10;35(32):3647-3653 - PubMed
  40. J Appl Toxicol. 2015 Jul;35(7):842-50 - PubMed
  41. Arch Physiol Biochem. 2010 May;116(2):73-8 - PubMed
  42. Cancer Res. 1974 Dec;34(12):3245-52 - PubMed

Publication Types